Share on StockTwits

Sagent Pharmaceuticals (NASDAQ:SGNT)‘s stock had its “hold” rating reiterated by investment analysts at Jefferies Group in a note issued to investors on Tuesday, AR Network reports. They currently have a $23.00 target price on the stock. Jefferies Group’s price objective points to a potential upside of 13.92% from the stock’s previous close.

Sagent Pharmaceuticals (NASDAQ:SGNT) traded up 1.66% during mid-day trading on Tuesday, hitting $20.19. 328,510 shares of the company’s stock traded hands. Sagent Pharmaceuticals has a 52 week low of $15.71 and a 52 week high of $26.08. The stock has a 50-day moving average of $22.13 and a 200-day moving average of $22.24. The company has a market cap of $642.8 million and a price-to-earnings ratio of 20.06.

Sagent Pharmaceuticals (NASDAQ:SGNT) last announced its earnings results on Tuesday, February 11th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.12. The company had revenue of $64.10 million for the quarter, compared to the consensus estimate of $60.25 million. On average, analysts predict that Sagent Pharmaceuticals will post $0.12 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on SGNT. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sagent Pharmaceuticals in a research note on Wednesday, February 12th. They now have a $22.00 price target on the stock, down previously from $24.00. Separately, analysts at Zacks downgraded shares of Sagent Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday, February 7th. They now have a $22.70 price target on the stock. Finally, analysts at Bank of America upgraded shares of Sagent Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Friday, February 7th. They now have a $25.00 price target on the stock, down previously from $26.00. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. Sagent Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $23.28.

Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.